1.Stevenson, CG, McArthur, MA, Zivnickova, H, Naus, M, Abraham, E, McGeer, A. Progress in the control of influenza and pneumococcal disease in long term care facilities: where do we stand? Presented at the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections; March 5-9, 2000; Atlanta, GA.
2.Henry, B. Summary report of the Ontario influenza 1998/9 season. Public Health and Epidemiology Report. Ontario. 1999;10:144–159.
3.Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48:(RR-4):1–28.
4.Statement on influenza vaccination for the 2000-2001 season. An Advisory Committee Statement (ASC). National Advisory Committee on Immunization. Can Commun Dis Rep 2000;26:1–16.
5.Aoki, FY. Amantadine and rimantadine. In: Nicholson, KG, Webster, RG, Hay, AJ, eds. Textbook of Influenza. Oxford, England: Blackwell Science, Ltd; 1998:457–476.
6.Atkinson, WL, Arden, NH, Patriarca, PALeslie, N, Lui, KJ, Gohd, R. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986;146:1751–1756.
7.Mast, EE, Harmon, MW, Gravenstein, S, Wu, SP, Arden, NH, Circo, R, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991;134:988–997.
8.Degelau, J, Somani, SKCooper, SL, Guay, DR, Crossley, KB. Amantadine-resistant influenza A in a nursing facility. Ardi Intern Med 1992;152:390–392.
9.Houck, P, Hemphill, M, LaCroix, S, Hirsh, D, Cox, N. Amantadine-resistant influenza A in a nursing homes. Identification of a resistant virus prior to drug use. Arch Intern Med 1995;155:533–537.
10.Hayden, FG, Osterhaus, AD, Treanor, JJ, Fleming, DM, Aoki, FY, Nicholson, KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997;337:874–880.
11.Randomised trial of the efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998;352:1877–1881.
12.Monto, AS, Robinson, DP, Herlocher, ML, Hinson, JM Jr, Elliott, MJ, Crisp, AZanamivir in the prevention of influenza among healthy adults: a randomized controlled txial. JAMA 1999;282:31–35.
13.Schilling, M, Povinelli, L, Krause, P, Gravenstein, M, Ambrozaitis A Jones, HH, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home outbreaks. Vaccine 1998;16:1771–1774.
14.McGeer, A, Campbell, B, Emori, TG, Hierholzer, WJ, Jackson, MM, Nicolle, LE, et al. Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991;19:1–7.
15.Katz, S, Downs, TD, Cash, HR, Frotz, RD. Progress in the development of the index of ADL. Gerontologist 1970;10:20–30.
16.KUmov, AI, Rocha, E, Hayden, FG, Schult, RA, Roumillat, LF, Cox, NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172:1352–1355.
17.Li, Y. 1998-1999 influenza season: Canadian laboratory diagnoses and strain characterization. Can Commun Dis Rep 1999;25-21:177–181.
18.Patriarca, PAWeber, JAParker, RAHall, WN, Kendal, AP, Bregman, DJ, et al. Efficacy of influenza vaccines in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985;253:1136–1139.
19.Arden, NH, Patriarca, PAKendal, AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. Options for the Control of Influenza. New York, NY: Alan R. Liss; 1986:155–168.
20.Potter, J, Stott, DJ, Roberts, MAElder, AG, O'Donnell, B, Knight, PV, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces mortality of elderly patients. J Infect Dis 1997;175:1–6.
21.Carman, WF, Elder, AG, Wallace, LA, McAulay, K, Walker A Murray, GD, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000;355:93–97.
22.Goevart, TM, Thijs, CT, Masurel, N, Sprenger, JJ, Dinant, GJ, Knottnerus, JAThe efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994;272:1661–1665.
23.Gross, PAHermogenes, AW, Sacks, HS, Lau, J, Levandowski, RA The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518–527.
24.Strassburg, MA, Greenland, S, Sondilo, FJ, Lieb, LE, Habel, LAInfluenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986;4:38–44.
25.Ohmit, SE, Arden, NH, Monto, AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc 1999;47:165–71.
26.Staynor, K, Foster, G, McArthur, M, McGeer, APetric, M, Simor, AE. Influenza A outbreak in a nursing home: the value of early diagnosis and the use of amantadine hydrochloride. Can J Infect Control 1994;9:109–111.
27.Dolin, R, Reichman, RC, Madore, HP, Maynard, R, Linton, PN, Webber-Jones, J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580–584.
28.Hayden, FG. Antivirals for pandemic influenza. J Infect Dis 1997;176(suppl 1):S56–S61.
29.Arden, NH, Patriarca, PA, Fasano, MB, Lui, KJ, Harmon, MW, Kendal, AP, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 1988;148:865–868.
30.Peters, NL, Oboler, S, Hair, C, Laxson, L, Kost, J, Meiklejohn, G. Treatment of an influenza A outbreak in a teaching nursing home. Effectiveness of a protocol for prevention and control. J Am Geriatr Soc 1989;37:210–218.
31.Centers for Disease Control and Prevention. Control of influenza A outbreaks in nursing homes: amantadine as an adjunct to vaccine—Washington, 1989-90. MMWR 1991;40:841–844.
32.Hayden, HG, Belshe, RB, Clover, RD, Hay, AJ, Oakes, MJ, Soo, W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696–1702.
33.Hayden, FG, Atmar, RL, Schilling, M, Johnson, C, Poretz, D, Paar, D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336–1343.
34.Lee, W, McArthur, M, Kam, AFriedman, RPhillips, ASimor, Aet al. Use of zanamivir to control an outbreak of influenza A in a nursing home. Presented at the Community and Hospital Infection Control Association of Canada; May 29-31, 2000; Toronto, Ontario, Canada. Abstract 11.
35.Gubareva, LV, Kaiser, L, Hayden, FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827–835.